Neuphoria Therapeutics Inc.

NEUP Healthcare Biotechnology

Neuphoria Therapeutics Inc.’s revenue for fiscal 2026 (year ended June 2026) was $1.2 million, down 92.5% from fiscal 2025. In the quarter to June 2026, revenue fell 107.3%, EPS grew 83.6% and free cash flow grew 133.9%, each against the same quarter a year earlier.

3.30 0.01 −0.30%
Market cap
$17.9M
P/E
0.0×
Fwd P/E
−1.9×
Dividend yield
—
F-score
n/a
Altman Z
−7.55
Beneish M
831.96
Dividend safety
n/a

A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.

Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Total current assets
21.07 21.66 23.39 13.95
Total non-current assets
7.64 13.15 13.21 13.39
Total Assets
28.71 34.81 36.60 27.34
Total current liabilities
0.76 1.51 2.59 5.12
Total non-current liabilities
3.35 3.87 4.31 9.71
Total liabilities
4.11 5.39 6.90 14.83
Common Equity (Total)
24.60 29.42 29.70 12.51
Shareholders Equity (Total)
24.60 29.42 29.70 12.51

Show all line items

In millions of $ except per-share values · columns are period end dates · fundamentals updated 2 Oct 2026